600211 西藏藥業
按盤價 
44.080 -0.120 (-0.271%) | 2025/12 - 人民幣(K¥) | 變動 | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | 2020/12 人民幣(K¥) | ||
| 營業總收入 | 2,981,538 | 6.23% | 3,134,328 | 2,554,609 | 2,138,587 | 1,373,105 | |
| 減：營業總成本 | 1,988,734 | 6.60% | 2,058,297 | 1,813,092 | 1,571,395 | 951,130 | |
| 其中:營業成本 | 172,475 | 6.27% | 155,085 | 146,694 | 223,218 | 194,965 | |
| 財務費用 | (69,078) | 46.41% | (33,712) | 4,291 | 6,750 | (13,543) | |
| 資產減值損失 | (4,845) | -2,552.49% | (193,970) | (276,664) | (460,641) | (722) | |
| 公允價值變動收益 | 1,662 | -108.75% | (210,533) | (14,167) | 153,254 | 2,549 | |
| 投資收益 | 7,481 | -50.47% | 40,442 | 7,023 | (6,781) | (1,600) | |
| 其中：對聯營企業和合營企業的投資收益 | (13,854) | 152.41% | (4,271) | (2,223) | (9,687) | (8,657) | |
| 營業利潤 | 1,043,832 | -10.05% | 899,093 | 464,653 | 256,800 | 472,117 | |
| 利潤總額 | 1,040,618 | -9.68% | 898,195 | 463,392 | 254,852 | 470,315 | |
| 減：所得稅費用 | 123,637 | 30.13% | 87,950 | 88,083 | 41,824 | 49,653 | |
| 淨利潤 | 916,981 | -13.25% | 810,245 | 375,309 | 213,027 | 420,663 | |
| 減：非控股權益 | (20,950) | -462.03% | 9,331 | 5,469 | 4,089 | 2,567 | |
| 股東淨利潤 | 937,931 | -10.78% | 800,914 | 369,840 | 208,938 | 418,096 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 2.910 | -10.74% | 2.480 | 1.490 | 0.840 | 1.690 | |
| 每股派息 (元) * | 1.757 | -10.22% | 1.939 | 0.746 | 0.338 | 0.510 | |
| 每股淨資產 (元) * | 11.785 | -3.05% | 13.490 | 12.147 | 10.609 | 10.390 | |
| 審計意見 # | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 17/03/2026 13:37 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
